ÅǸ޴º
¹øÈ£ | ±¸ºÐ | Á¦¸ñ |
---|---|---|
14 | (±¹¿Ü)SCI | Reliability and Validity of the Korean Version of Kidney Disease Quality of Life Instrument (KDQOL-SFTM) |
13 | (±¹³»)±âŸ | Activation of the renin-angiotensin system within podocytes in diabetes |
12 | (±¹³»)±âŸ | Ç×°áÇÙÁ¦¿¡ ¹ÝÀÀÇÏÁö ¾Ê¾Ò´ø °áÇÙ¼º ¼ö¸·¿°°ú µ¿¹ÝÇÑ Ç×ÀÌ´¢È£¸£¸óºÎÀûÀýºÐºñÁõÈıº 1¿¹ |
11 | (±¹³»)±âŸ | ´ç´¢ ¹é¼ »ç±¸Ã¼ ¹× °íÆ÷µµ´çÀ¸·Î ÀÚ±ØÇÑ Á·¼¼Æ÷¿¡¼ ½ÎÀÌŬ·Î½ºÆ÷¸°ÀÌ P-cadherinÀÇ ¹ßÇö¿¡ ¹ÌÄ¡´Â ¿µÇâ |
10 | (±¹³»)±âŸ | °íÆ÷µµ´çÀÌ Á·¼¼Æ÷³» ±¹¼Ò ·¹´Ñ-¾ÈÁö¿ÀÅٽŰè (Renin-Angiotensin system)¿¡ ¹ÌÄ¡´Â ¿µÇâ |
9 | (±¹¿Ü)SCI | Influence of endothelial nitric oxide synthase gene polymorphisms (786TNC, 4a4b, 894GNT) in Korean patients with coronary artery disease |
8 | (±¹³»)KCI | ¼ºÀÎÇü ½ºÆ¿º´°ú µ¿¹ÝµÈ Á¶Á÷±¸¼º ±«»ç¼º ¸²ÇÁÀý¿° 1¿¹ |
7 | (±¹³»)KCI | Mycoplasma Infection°ú µ¿¹ÝµÈ ±Þ¼º °£Áú¼º ½Å¿° 1¿¹ |
6 | (±¹³»)KCI | Å©·¹¸ÞÁøÀÇ Åõ¼®µµÀÔ Áö¿¬È¿°ú¿¡ µû¸¥ ÁøÇ༺ ½ÅºÎÀüÁõȯÀÚÀÇ ºñ¿ë°¨¼ÒºÐ Ãß°è |
5 | (±¹³»)KCI | EPO »ç¿ëÀÌ ¾ø¾ú´ø ¸»±â½ÅºÎÀüÀ¸·Î Ç÷¾×Åõ¼® ÁßÀΠȯÀÚ¿¡¼ ¹ß»ýÇÑ ÀûÇ÷±¸Áõ°¡Áõ 1¿¹ |
Copyright ¨Ï chamc, All rights reserved.